EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study

Flora Lambert, Emilie Guillon, Blandine Gatta-Cherifi, CranioGLP1_FORCE Group, Hedi Soula, Christine Poitou, Pauline Faucher iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70216 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Flora Lambert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition Department, Reference Center for Rare Diseases PRADORT, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France. Hauptthemen laut MEDLINE: Craniopharyngioma, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Pituitary Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real‐world effectiveness and safety of GLP‐1 RAs in this population. Materials and Methods CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP‐1 RAs across 16 French obesity centres. Demographic, clinical, and therapeutic data were collected from medical records. Weight outcomes, adverse events, and predictors of response were analysed.

Results

Patients had a mean age of 44.4 ± 13.5 years and a mean BMI of 40.1 ± 8.6 kg/m 2 , 42% had type 2 diabetes. Over a mean follow‐up of 44 months, mean weight loss was −4.6% (±12.5), with high interindividual variability; 51% achieved ≥5% weight loss, and 28% ≥10%. Semaglutide (mean dose 1.2 mg/week) was associated with the greatest reduction (−6.8%), particularly in patients without diabetes (−8.5% ± 12.3 vs. −3.9% ± 10.0 in those with diabetes; p = 0.032). Endocrine adverse events occurred in 12% and 10% of patients with adrenal or vasopressin deficiency decompensation, respectively, with 8% requiring hospitalisation. Gastrointestinal intolerance led to treatment discontinuation in 13% of cases.

Conclusions

GLP‐1 RAs at submaximal doses induce moderate, yet clinically meaningful weight loss in adults with aHO, with semaglutide showing the highest efficacy. Given the non‐negligible risk of hormonal decompensation, specific endocrine monitoring is essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniopharyngiomaGlucagon-Like Peptide-1 Receptor AgonistsObesityPituitary NeoplasmsGlucagon-Like PeptidesHypoglycemic AgentsHumansMaleFemaleAdultRetrospective StudiesMiddle AgedWeight LossTreatment OutcomeDiabetes Mellitus, Type 2FranceGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 analogueanti‐obesity drugobesity therapyreal‐world evidencesemaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Nutrition Department, Reference Center for Rare Diseases PRADORT, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
  • Nutrition and Obesities, Systemic Approaches-NutriOmique Research Group, Sorbonne Université, Inserm, Paris, France.
  • Endocrinology, Diabetology, Nutrition and Metabolic Diseases Department, Haut-Lévêque Hospital, Bordeaux, France.

ORCID-Profile: Pauline Faucher

Zitieren

APA

Lambert, F., Guillon, E., Gatta-Cherifi, B., CranioGLP1_FORCE Group, Soula, H., Poitou, C., & Faucher, P. (2026). Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70216

Vancouver

Lambert F, Guillon E, Gatta-Cherifi B, CranioGLP1_FORCE Group, Soula H, Poitou C, et al. Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70216

BibTeX
@article{Lambert2026,
  author = {Lambert, Flora and Guillon, Emilie and Gatta-Cherifi, Blandine and CranioGLP1_FORCE Group, CranioGLP1_FORCE Group and Soula, Hedi and Poitou, Christine and Faucher, Pauline},
  title = {Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70216}
}
Kostenlos starten →